Birmingham cannabis firm faces administration after years of cash struggles
A notice of intention to appoint administrators has been filed at the High Court against Celadon Pharma, the Birmingham-based cannabis medicine manufacturer, court records show.
The filing, made on 14 August by insolvency practitioners Adam Stephens and Ben Woodthorpe of Lester Aldridge, gives the company ten working days of protection from creditor action while it works through its options.
It follows a prolonged period of financial difficulty for the group, which has repeatedly warned over the past two years that it was relying on creditor support to continue trading.
Cash reserves fell as low as £48,000 at one point in September 2024, and the company took out a £500,000 emergency credit facility at a 10% interest rate in mid-2025, on top of an existing £7m committed facility, simply to stay operational.
Matters came to a head in June 2025, when Celadon shares fell 17% after the company said it would miss the deadline to file its annual accounts, triggering a trading suspension from 1 July. The company also signalled its intention to delist from AIM entirely, following a fresh £1m secured loan and talks over a possible £20m convertible loan that would have required it to become a private company. Celadon subsequently delisted from AIM and went private last year.
Celadon operates a 100,000 sq ft licensed cultivation and manufacturing facility in Birmingham, one of the earliest sites in the UK approved by the Home Office and MHRA to grow and produce high-THC medicinal cannabis, since the company’s founding in 2018.
Chief executive James Short said discussions were ongoing around several financing options, with no decision yet made, and that the company would not comment further until those talks concluded.



